76%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
76%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
76%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
76%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Español (Latinoamérica)
Smith & Nephew PLC
Cerrado
1,120 0.36
Resumen
Variación precio
24h
Mínimo
1118
Máximo
1125.5
Ingresos | 107M |
|---|---|
Ventas | 1.4B |
P/B Media del Sector | 30.757 36.132 |
BPA | 0.376 |
Rentabilidad por dividendo | 2.66 |
Margen de beneficio | 7.57 |
Empleados | 17,349 |
EBITDA | 260M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +12.1% upside |
Rentabilidad por dividendo Media del Sector | 2.66% 5.74% |
|---|---|
Próximas Ganancias | 5 ago 2025 |
Capitalización de Mercado | 397M 9.4B |
|---|---|
Apertura anterior | 1119.64 |
Cierre anterior | 1120 |
Smith & Nephew PLC Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Smith & Nephew PLC Esperado
Precio Objetivo
By TipRanks
12.1% repunte
Estimación a 12 meses
Media 1,252.14 GBX 12.1%
Máximo 1,450 GBX
Mínimo 1,065 GBX
De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Smith & Nephew PLC Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
EBITDA
Beneficio operativo
$
Acerca de Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
